Last reviewed · How we verify
CDX 6114
At a glance
| Generic name | CDX 6114 |
|---|---|
| Sponsor | Société des Produits Nestlé (SPN) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of CDX 6114 in PKU Patients (PHASE1)
- Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of CDX-6114 in Patients With Phenylketonuria (PKU) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CDX 6114 CI brief — competitive landscape report
- CDX 6114 updates RSS · CI watch RSS
- Société des Produits Nestlé (SPN) portfolio CI